Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Edwards Lifesciences (EW)

Edwards Lifesciences Q4 sales rise 9% to $1.39 billion; 2025 guidance unchanged

Positive Impact 3 of 5 earnings Written later

Edwards Lifesciences reported fourth-quarter 2024 results on February 11, 2025, with net sales up 9% to $1.39 billion and GAAP diluted EPS of $0.58, compared with $0.55 a year earlier. The company reiterated its 2025 sales and adjusted EPS guidance and gave first-quarter 2025 projections, so the results and outlook are steady for shareholders.

Key points

  • Q4 2024 net sales were $1,385.8 million, up from $1,266.4 million a year earlier.
  • Q4 2024 GAAP diluted EPS was $0.58 versus $0.55; adjusted diluted EPS was $0.59.
  • 2025 guidance reiterated: constant currency sales growth of 8% to 10% and adjusted EPS of $2.40 to $2.50.
  • Q1 2025 outlook: total sales of $1.35 billion to $1.43 billion and adjusted EPS of $0.58 to $0.64.

The filing

CompanyEdwards Lifesciences (EW)
Form8-K, current report
Filed with the SECFeb 11, 2025, 4:24 PM ET
Accession number0001099800-25-000003

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 11, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.